Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 325

Sort by

Sort Order Select

Journal Articles

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

Blood (2021) 138 (7): 571–583.

https://doi.org/10.1182/blood.2021010735

Published: 2021

Includes: Supplemental data

Journal Articles

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Gabriel Levy, Serge Carillo, Benjamin Papoular, Bruno Cassinat, Jean-Marc Zini, Emilie Leroy, Leila N. Varghese, Ilyas Chachoua, Jean-Philippe Defour, Steven O. Smith, Stefan N. Constantinescu

Blood (2020) 135 (12): 948–953.

https://doi.org/10.1182/blood.2019003240

Published: 2020

Includes: Supplemental data

Journal Articles

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

Carlo Visco, Francesco Rodeghiero, Alessandra Romano, Federica Valeri, Michele Merli, Giulia Quaresimini, Stefano Volpetti, Roberto M. Santi, Giuseppe Carli, Elisa Lucchini, Francesco Passamonti, Alessandro Rambaldi, Giovanna Motta, Alessandra Borchiellini, Emanuele S. G. d’Amore, Marco Ruggeri

Blood (2019) 134 (20): 1708–1711.

https://doi.org/10.1182/blood.2019001617

Published: 2019

Includes: Supplemental data

Journal Articles

A Rare Presentation of Acute Immune Thrombocytopenia, Refractory to First Line Therapy, Despite Euthyroid State

Emily Molina, DO, MSPH, Gursharon Sanghera, MD, Patrick Hanley, MD, Rafat Ahmed, MD

Blood (2019) 134 (Supplement_1): 4900.

https://doi.org/10.1182/blood-2019-126200

Published: 2019

Journal Articles

Outcomes in Pediatric Patients with Severe Aplastic Anemia Treated with Standard Immunosuppression and Eltrombopag

Emma M. Groarke, MD, Bhavisha A Patel, MD, Carrie Diamond, MD, Fernanda Gutierrez-Rodrigues, PhD, Alana Vicente, MD, Olga Rios, RN, Jennifer Lotter, PA-C, Daniela Baldoni, Ruba Shalhoub, Colin Wu, PhD, Neal S. Young, MD

Blood (2019) 134 (Supplement_1): 454.

https://doi.org/10.1182/blood-2019-124811

Published: 2019

Journal Articles

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Yihong Guan, PhD, Bhumika J. Patel, MD, Metis Hasipek, PhD, Dale Grabowski, BS, Hassan Awada, MD, Cassandra M Kerr, MS, Valeria Visconte, PhD, Aziz Nazha, MD, Yogenthiran Saunthararajah, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 453.

https://doi.org/10.1182/blood-2019-131525

Published: 2019

Journal Articles

Second-Line Therapy for Immune Thrombocytopenia: Real-World Experience

Hasmik Nazaryan, Yang Liu, MS, Emily Sirotich, BS, Joanne M Duncan, MSc, Donald M. Arnold, MD

Blood (2019) 134 (Supplement_1): 2120.

https://doi.org/10.1182/blood-2019-128336

Published: 2019

Journal Articles

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Blood (2019) 134 (Supplement_1): 3000.

https://doi.org/10.1182/blood-2019-126744

Published: 2019

Journal Articles

Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study

Guillaume Moulis, MD PhD, Manuela Rueter, MSc, Margaux Lafaurie, PharmD, Maryse Lapeyre-Mestre, MD PhD, Carmen investigators Group

Blood (2019) 134 (Supplement_1): 2372.

https://doi.org/10.1182/blood-2019-126000

Published: 2019

Journal Articles

Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers

Tomas Jose Gonzalez-Lopez, Fernando Fernandez-Fuertes, Maria Cristina Pascual Izquierdo, PhD MD, Isabel Caparros, Silvia Bernat, Carmen Pastoriza, Maria Paz Martínez-Badas, Pável E Olivera, MD, Gonzalo Caballero, MD, Jose Angel Hernandez-Rivas, MD PhD, Daniel Martínez-Carballeira, MD, Inmaculada Soto Ortega, Gloria Perez Segura, Isabel Regalado, Blanca Sánchez-González, Isidro Jarque, Luis Javier garcia Frade, MD, Miguel A. Sanz

Blood (2019) 134 (Supplement_1): 2352.

https://doi.org/10.1182/blood-2019-129274

Published: 2019

Journal Articles

UM171 Regulates the Hematopoietic Differentiation of Human Acquired Aplastic Anemia-Derived Induced Pluripotent Stem Cells

Tellechea Maria Florencia, MSc, Flavia S. Donaires, PhD, Tiago C. Silva, PhD, Lilian F. Moreira, PhD, Yordanka Armenteros, PhD, Rodrigo T. Calado, MD PhD

Blood (2019) 134 (Supplement_1): 2500.

https://doi.org/10.1182/blood-2019-127466

Published: 2019

Journal Articles

Dose-Dependent Iron Chelating Effects of Eltrombopag on in Vitro Human Megakaryopoiesis

Zhi-Jian Liu, PhD, Emoke Deschmann, MD, Haley E. Ramsey, PhDMSc, Henry Feldman, Bethan Psaila, MD PhD, Nichola Cooper, MD MRCP, Evangelia Vlachodimtropoulou Koumoutsea, MBBS,PhDBSc, John B. Porter, MA MDFRCP FRCPath, James B. Bussel, MD, Michael Georgieff, MD, Martha Sola-Visner, MD

Blood (2019) 134 (Supplement_1): 2475.

https://doi.org/10.1182/blood-2019-131895

Published: 2019

Journal Articles

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

Hanny Al-Samkari, MD, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Wei Tian, PhD, Lee F. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 2356.

https://doi.org/10.1182/blood-2019-131215

Published: 2019

Journal Articles

Retrospective EHR Study on Effectiveness of Eltrombopag in Cancer Treatment-Related Thrombocytopenia

Anjali Pawar, MD, Vamsidhar Velcheti, MD, Lincy S. Lal, Lisa Le, Katherine Andrade, Isha Desai, Pallavi Patwardhan, PhD

Blood (2019) 134 (Supplement_1): 1100.

https://doi.org/10.1182/blood-2019-124781

Published: 2019

Journal Articles

The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey

James B. Bussel, MD, Alexandra Kruse, Caroline Kruse, Jody Shy, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 1076.

https://doi.org/10.1182/blood-2019-131351

Published: 2019

Journal Articles

Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling

Ujunwa Cynthia Okoye-Okafor, MS,PhD, Komal Kumar Javarappa, PhD, Dimitrios Tsallos, BSc(Hons),MSc, Joseph J Saad, MSc, BSc, Lumie Benard, Victor Thiruthuvanathan, M.S, Sally Cole, Madhuri Tatiparthy, M.S., Stephen Ruiz, B.Sc, Stefanie DeFronzo, Celine Pallaud, PhD, Pedro Marques Ramos, PhD, Amit Verma, MBBS, Aditi Shastri, MD, Caroline A Heckman, PhD, Britta Will, PhD

Blood (2019) 134 (Supplement_1): 1280.

https://doi.org/10.1182/blood-2019-131461

Published: 2019

Journal Articles

Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry

Blood (2019) 134 (Supplement_1): 1083.

https://doi.org/10.1182/blood-2019-122821

Published: 2019

Journal Articles

Safety and Efficacy of the Off-Label Use of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia in Pregnancy: Results from a Multicentre Observational Study

Marc Michel, Marco Ruggeri, Tomás José González-López, MD, Stephane Cheze, MD, Waleed Ghanima, MD PhD, Tor Henrik Anderson Tvedt, Mikael Ebbo, MD PhD, James B. Bussel, MD, Bertrand Godeau, MD

Blood (2019) 134 (Supplement_1): 1081.

https://doi.org/10.1182/blood-2019-122595

Published: 2019

Journal Articles

Perioperative Eltrombopag or Intravenous Immune Globulin for Patients with Immune Thrombocytopenia: A Multicenter Randomized Trial

Donald M. Arnold, MD, Nancy Heddle, MSc, Richard Cook, Cyrus C. Hsia, MDBSc,FRCPC, Mark Blostein, MDFRCPC, Erin Jamula, MSc, Michelle Sholzberg, MDBSc,FRCPC,MSc, Yulia Lin, MD, Jeannine Kassis, MD, Loree Larratt, MD FRCP(C), Sufia Amini, MD, Martin R. Schipperus, Wendy Lim, MD MSc, Prakash Vishnu, MD, Margaret Warner, FRCPC, Julie Carruthers, MLT, B.Com(Hon), Shannon J Lane, MPH, Na Li, PhD, John G. Kelton, MD

Blood (2019) 134 (Supplement_1): 896.

https://doi.org/10.1182/blood-2019-122609

Published: 2019

Journal Articles

Comparing the Risk of Complications for Second-Line Treatments of Immune Thrombocytopenia in Veterans: A U.S. National Study

Natalia Ruiz-Negron, PharmD, Jacob Crook, MStat, Matthew T. Rondina, MD, Pallavi Patwardhan, PhD, Qayyim Said, PhD, Isha Desai, MPH, Richard Nelson, PhD, Joanne LaFleur, PharmD, MSPH

Blood (2019) 134 (Supplement_1): 85.

https://doi.org/10.1182/blood-2019-121894

Published: 2019

NARROW

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

A Rare Presentation of Acute Immune Thrombocytopenia, Refractory to First Line Therapy, Despite Euthyroid State

Outcomes in Pediatric Patients with Severe Aplastic Anemia Treated with Standard Immunosuppression and Eltrombopag

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Second-Line Therapy for Immune Thrombocytopenia: Real-World Experience

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study

Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers

UM171 Regulates the Hematopoietic Differentiation of Human Acquired Aplastic Anemia-Derived Induced Pluripotent Stem Cells

Dose-Dependent Iron Chelating Effects of Eltrombopag on in Vitro Human Megakaryopoiesis

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

Retrospective EHR Study on Effectiveness of Eltrombopag in Cancer Treatment-Related Thrombocytopenia

The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey

Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling

Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry

Safety and Efficacy of the Off-Label Use of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia in Pregnancy: Results from a Multicentre Observational Study

Perioperative Eltrombopag or Intravenous Immune Globulin for Patients with Immune Thrombocytopenia: A Multicenter Randomized Trial

Comparing the Risk of Complications for Second-Line Treatments of Immune Thrombocytopenia in Veterans: A U.S. National Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only